SI3283058T1 - Tableta ribocikliba - Google Patents

Tableta ribocikliba

Info

Publication number
SI3283058T1
SI3283058T1 SI201631661T SI201631661T SI3283058T1 SI 3283058 T1 SI3283058 T1 SI 3283058T1 SI 201631661 T SI201631661 T SI 201631661T SI 201631661 T SI201631661 T SI 201631661T SI 3283058 T1 SI3283058 T1 SI 3283058T1
Authority
SI
Slovenia
Prior art keywords
ribociclib
tablet
ribociclib tablet
Prior art date
Application number
SI201631661T
Other languages
English (en)
Slovenian (sl)
Inventor
Bindhumadhavan Gururajan
Arnaud Grandeury
Rui Costa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3283058(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI3283058T1 publication Critical patent/SI3283058T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201631661T 2015-04-16 2016-04-14 Tableta ribocikliba SI3283058T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
EP16718020.7A EP3283058B1 (en) 2015-04-16 2016-04-14 Ribociclib tablet
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
SI3283058T1 true SI3283058T1 (sl) 2023-03-31

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631661T SI3283058T1 (sl) 2015-04-16 2016-04-14 Tableta ribocikliba

Country Status (29)

Country Link
US (6) US10799506B2 (enExample)
EP (3) EP4620458A3 (enExample)
JP (1) JP2018514523A (enExample)
KR (2) KR102750931B1 (enExample)
CN (2) CN115554257A (enExample)
AR (1) AR104257A1 (enExample)
AU (5) AU2016248017A1 (enExample)
BR (1) BR112017021283A2 (enExample)
CA (1) CA2982425C (enExample)
CL (1) CL2017002593A1 (enExample)
CO (1) CO2017010510A2 (enExample)
DK (1) DK3283058T3 (enExample)
EA (1) EA201792290A1 (enExample)
EC (1) ECSP17075052A (enExample)
ES (1) ES2938261T3 (enExample)
FI (1) FI3283058T3 (enExample)
HR (1) HRP20230053T1 (enExample)
HU (1) HUE061213T2 (enExample)
IL (1) IL254818A0 (enExample)
MX (1) MX2017013350A (enExample)
PE (1) PE20180035A1 (enExample)
PH (1) PH12017501820A1 (enExample)
PL (1) PL3283058T3 (enExample)
PT (1) PT3283058T (enExample)
SG (1) SG11201708084PA (enExample)
SI (1) SI3283058T1 (enExample)
TN (1) TN2017000422A1 (enExample)
TW (1) TW201642864A (enExample)
WO (1) WO2016166703A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514523A (ja) * 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
EP4021450B1 (en) 2019-08-26 2025-11-05 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL293940A (en) 2019-12-16 2022-08-01 Lunella Biotech Inc Selective cancer drugs cdk4/6 inhibitors
CA3164619A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
US20230310327A1 (en) * 2020-08-03 2023-10-05 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
KR20230079187A (ko) * 2020-09-29 2023-06-05 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. 고지혈증 및 심혈관 질환의 치료 및 예방을 위한 스타틴 및 피브레이트의 약학적 병용
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
TWI866427B (zh) 2022-08-31 2024-12-11 美商亞文納營運公司 雌激素受體降解劑之給藥方案
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
AU2024244511A1 (en) 2023-03-27 2025-09-25 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US8343533B2 (en) * 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
IN2015DN01046A (enExample) * 2012-07-13 2015-06-26 Gtx Inc
EP3251673A1 (en) * 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
PT2976106T (pt) * 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
JP2018514523A (ja) * 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
AU2020250190A1 (en) 2020-11-05
US20250134893A1 (en) 2025-05-01
ECSP17075052A (es) 2018-02-28
BR112017021283A2 (pt) 2018-06-26
CN107530292A (zh) 2018-01-02
EP4620458A2 (en) 2025-09-24
PE20180035A1 (es) 2018-01-09
KR20250009572A (ko) 2025-01-17
AU2024227794A1 (en) 2024-11-21
KR102750931B1 (ko) 2025-01-09
US20250127785A1 (en) 2025-04-24
US12064434B2 (en) 2024-08-20
AR104257A1 (es) 2017-07-05
SG11201708084PA (en) 2017-10-30
EP3283058A1 (en) 2018-02-21
CL2017002593A1 (es) 2018-05-18
EP4197530B1 (en) 2025-11-12
CO2017010510A2 (es) 2018-03-20
CA2982425C (en) 2023-10-31
EA201792290A1 (ru) 2018-02-28
AU2022215155B2 (en) 2024-08-01
PL3283058T3 (pl) 2023-03-20
CN107530292B (zh) 2022-11-01
AU2022215155A1 (en) 2022-09-01
ES2938261T3 (es) 2023-04-05
TN2017000422A1 (en) 2019-01-16
EP4197530A1 (en) 2023-06-21
PH12017501820A1 (en) 2018-04-23
TW201642864A (zh) 2016-12-16
US20250090531A1 (en) 2025-03-20
IL254818A0 (en) 2017-12-31
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
US10799506B2 (en) 2020-10-13
FI3283058T3 (fi) 2023-03-01
HUE061213T2 (hu) 2023-05-28
EP4620458A3 (en) 2025-10-22
WO2016166703A1 (en) 2016-10-20
DK3283058T3 (da) 2023-02-13
AU2019201929B2 (en) 2020-07-09
JP2018514523A (ja) 2018-06-07
KR20170137101A (ko) 2017-12-12
HRP20230053T1 (hr) 2023-03-03
CA2982425A1 (en) 2016-10-20
US20200390771A1 (en) 2020-12-17
AU2019201929A1 (en) 2019-04-11
US20230104792A1 (en) 2023-04-06
MX2017013350A (es) 2018-01-25
PT3283058T (pt) 2023-02-03
AU2016248017A1 (en) 2017-10-19
EP3283058B1 (en) 2022-11-16
CN115554257A (zh) 2023-01-03

Similar Documents

Publication Publication Date Title
DK3256579T3 (en) Cysteinprotease
DK3256580T3 (en) Cysteinprotease
GB201707959D0 (en) No details
AU356804S (en) Tablet
DK3250592T3 (en) Anti-transthyretin-antistoffer
IL254818A0 (en) Ribociclib tablet
GB201706130D0 (en) No details
DK3284069T3 (en) Pos-terminal
SG11201800591TA (en) Tablet
GB201615071D0 (en) No details
GB201612542D0 (en) no details
DK3272750T3 (en) Morphinan-derivat
GB201709180D0 (en) No details
GB201420300D0 (en) Tablet
AU361999S (en) Ballustrade
GB201616225D0 (en) No details
DK3133099T3 (en) Polymermodificeret polyoldispersion
AU356801S (en) Tablet
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201708207D0 (en) No details
DK3282866T3 (en) Proteinfibre
GB201511252D0 (en) Tablet
DK3250312T3 (en) Urea-metalnitrat-scr-system
DK3294653T3 (en) Justerbar inline-port
GB201702336D0 (en) No details